Gold prices steady ahead of Fed decision; weekly weakness noted
ORLANDO, Fla. - Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pharmaceutical company specializing in transdermal drug delivery with a current market capitalization of $63 million, has outlined its progress and future goals in a recent letter to shareholders from CEO Gareth Sheridan. The company’s stock has shown remarkable strength, delivering a 64% return over the past year. According to InvestingPro analysis, the company appears undervalued based on its Fair Value assessment. The company, which has been developing its AVERSA technology for abuse-deterrent transdermal patches, is on course to commercialize its lead product, AVERSA Fentanyl, in collaboration with Kindeva Drug Delivery.
AVERSA Fentanyl is poised to be the first opioid pain patch with abuse deterrent properties and has a projected peak annual sales potential of $80M - $200M. Following this, Nutriband plans to launch AVERSA Buprenorphine, with estimated peak sales of $70M - $130M. The company has confirmed the commercial viability of incorporating AVERSA technology into existing FDA-approved transdermal patches, expecting to achieve high margins typical of New Drug Application (NDA) pharmaceutical products.
In the past year, Nutriband has made significant advances in manufacturing processes and established the commercial supply chain necessary to meet FDA regulatory standards. A milestone was recently achieved with Kindeva Drug Delivery to formalize their exclusive product development partnership, which includes shared development costs and milestone payments.
Nutriband’s 2025 goals include initiating a pivotal Human Abuse Liability (HAL) clinical trial for Aversa Fentanyl and filing an Investigational New Drug application with the FDA. The company is also exploring international partnerships and licensing opportunities for its AVERSA intellectual property.
Additionally, Nutriband’s subsidiary, Pocono Pharma, has seen strong revenue growth in its contract manufacturing services for kinesiology tape, including an expanding collaboration with KT Tape. With current revenues of $2.14 million and a healthy current ratio of 4.88, the company maintains strong liquidity to support its operations. The company’s intellectual property portfolio for AVERSA technology has been strengthened with new patent approvals in China and the United States, now covering 46 countries. InvestingPro subscribers can access additional financial metrics and 8 more exclusive ProTips about Nutriband’s growth potential and market position.
This press release statement indicates that Nutriband is strategically targeting major medical markets worldwide to address the unmet need for adequate pain management solutions. The company’s advancements suggest a potential positive impact on shareholder value and contributions to safer pharmaceutical practices.
In other recent news, Nutriband Inc. has made significant strides in its development of transdermal pharmaceutical products. The company recently secured a patent in Macao for its AVERSA™ abuse deterrent technology, expanding its intellectual property portfolio to 46 countries. Additionally, Nutriband has announced the acquisition of a trademark for "Nutriband™" from the US Patent and Trademark Office, further strengthening its brand associated with the AVERSA™ platform. In partnership with Kindeva Drug Delivery, Nutriband is working on developing AVERSA™ Fentanyl, a fentanyl transdermal system aimed at deterring abuse, which could potentially achieve peak annual U.S. sales of $80 million to $200 million, pending FDA approval and market acceptance.
The company also announced an exclusive partnership with Kindeva Drug Delivery to develop the Aversa™ Fentanyl patch, which incorporates proprietary abuse-deterrent technology. This partnership involves shared development costs and milestone payments, aiming to create a safer transdermal delivery system for fentanyl. Nutriband’s efforts to enhance brand visibility include a new Associate Partnership with Charlotte FC, which aligns with its local manufacturing presence in North Carolina. Furthermore, Nutriband has received a Notice of Allowance from the United States Patent and Trademark Office for its Aversa™ abuse deterrent technology, indicating an impending U.S. patent grant. These developments reflect Nutriband’s ongoing commitment to innovation and the expansion of its technological advancements in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.